文献速递肾癌与肾肿瘤

英国队列中肾肿块经皮微波消融的经验

Percutaneous microwave ablation of renal masses in a UK cohort.
PubMed 文献 · BJU Int · 2020-09-21

该研究回顾性分析英国单中心113例疑似肾细胞癌的微波消融(MWA)前瞻性数据库,中位肿瘤直径25 mm,95%活检,75%病理确诊癌。中位随访12个月,局部复发1例,转移2例,并发症与消融时间和能量相关,结论认为MWA安全有效。

要点

  • MWA治疗T1a/小T1b肾肿块,95%患者次日出院,严重并发症率低。
  • 中位随访12个月,局部复发率0.9%,转移进展2例(1.8%)。
  • 并发症与总消融时间(OR 1.152/min)和总消融能量(OR 1.017/kJ)相关。

核心结论

  • MWA治疗T1a/小T1b肾肿块耐受良好,疾病控制良好,安全有效。

主要发现

  • 中位年龄68岁(范围33-85),73%为男性,中位Charlson合并症指数0。
  • 中位肿瘤直径25 mm(IQR 20-32),95%行肾肿块活检,75%病理确诊癌,中位R.E.N.A.L.评分7(IQR 6-8)。
  • 中位消融时间6分钟,95%患者住院1天;Clavien-Dindo I、II、IIIb、IV级并发症分别占18%、1.8%、0.9%、0.9%。
  • 中位随访12个月,中位肾功能变化-4%(IQR -18%至0%);1例(0.9%)局部复发再消融,2例转移进展,2例(1.8%)随访不确定。
  • 术后并发症与总消融时间(OR 1.152/分钟,95%CI 1.040-1.277)和总消融能量(OR 1.017/kJ,95%CI 1.001-1.033)相关。

关键数值与推荐

  • MWA适用于T1a/小T1b肾肿块,中位肿瘤直径25 mm,中位R.E.N.A.L.评分7。
  • 并发症与消融时间(每增加1分钟OR 1.152)和消融能量(每增加1 kJ OR 1.017)独立相关。

临床怎么用

  • MWA可作为T1a/小T1b肾肿块的治疗选择,尤其适合合并症少、希望短住院的患者。
  • 控制消融时间和能量可能降低并发症风险,术后需按方案CT随访监测复发。

局限性

  • 中位随访仅12个月,肿瘤学结局需更长期验证。
  • 单中心回顾性设计,样本量有限,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report a tertiary referral centre's experience of microwave ablation (MWA) for suspected renal cell carcinoma (RCC), describing complications and oncological outcomes. PATIENTS AND METHODS: Consecutive MWA procedures (n = 113) for renal masses (October 2016 to September 2019) were maintained on a prospective database. Data describing patient, disease, procedure, complications, and oncological outcomes were analysed. RESULTS: The median (range) age was 68 (33-85) years, 73% were male, and the median Charlson Comorbidity Index was 0. The median (interquartile range [IQR]) tumour diameter was 25 (20-32) mm. In all, 95% had renal mass biopsy, with histologically confirmed cancer in 75%. The median (IQR) R.E.N.A.L. (Radius, Exophytic/Endophytic, Nearness, Anterior/Posterior, Location) nephrometry score was 7 (6-8). The median ablation time was 6 min and length of stay was 1 day for 95% of the patients. Clavien-Dindo complication Grades I, II, IIIb and IV occurred in 18%, 1.8%, 0.9% and 0.9%, respectively. The median follow-up was 12 months and the median (IQR) renal function change was -4 (-18 to 0)%. One patient (0.9%) had local recurrence, treated with re-ablation; two developed metastatic progression; and two (1.8%) had indeterminate findings on follow-up (one lung nodule and one possible local recurrence), managed with ongoing protocolised computed tomography surveillance. Post-procedure complications were associated with total ablation time (odds ratio [OR] 1.152/min, 95% confidence interval [CI] 1.040-1.277) and total ablation energy (OR 1.017/kJ, 95% CI 1.001-1.033). CONCLUSIONS: We describe the largest UK series of MWA treatment for T1a/small T1b renal masses to date. MWA was well tolerated, with 95% discharged the following day and low complication/re-admission rates. Current follow-up demonstrates favourable disease control. MWA appears to be safe and effective and should be considered in future prospective comparisons of treatments for T1a/small T1b renal masses.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. John JB, Anderson M, Dutton T, et al. Percutaneous microwave ablation of renal masses in a UK cohort. BJU Int. 2020. PMID: 32871034. doi:10.1111/bju.15224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。